Jean‐Philippe Guégan

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 515 citations · Full text

Lymphoid Neoplasia, Cancer Immunosurveillance, Pd-l1 Expression +9

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Antoîne Italiano, Alban Bessede, M. Pulido et al. · Nature Medicine · 2022 · 235 citations

Lymphoid Neoplasia, Pembrosarc Trial Cohort, Medicine +7

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan et al. · Clinical Cancer Research · 2021 · 150 citations · Full text

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

Mathieu Larroquette, Jean‐Philippe Guégan, Benjamin Besse et al. · Journal for ImmunoTherapy of Cancer · 2022 · 137 citations · Full text

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Yohann Loriot, Aurélien Marabelle, Jean‐Philippe Guégan et al. · Annals of Oncology · 2021 · 84 citations · Full text

Prognostic Biomarkers, Plasma Proteomics Identifies, Inhibitory Factor +10